Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 3 August 2016 that it had entered into a definitive agreement to buy US generics business Anda from Allergan.
Teva to acquire US-based generics maker Anda
Home/Pharma News | Posted 12/08/2016 0 Post your comment
Anda is the fourth largest distributor of generics in the US. The company distributes generic, brand, specialty and over-the-counter pharmaceutical products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices across the US.
Teva will pay US$500 million for Anda and expects the company to generate more than US$1 billion in third-party net revenue for 2016.
Anda will continue to operate as a stand-alone business and, as part of the deal, Teva will acquire three distribution centres in Olive Branch, Massachusetts; Weston, Florida; and Groveport, Ohio, with a total of over 650 employees.
The move is expected by Sigurdur Olafsson, President & CEO of Global Generic Medicines, to enable Teva ‘to improve capabilities and flexibility given the changes the pharmaceutical industry is currently undergoing, in order to provide access to more patients throughout the country’.
Related article
Teva and Takeda establish ‘Teva Takeda Yakuhin’ in Japan
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
Source: Teva
Guidelines
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
Policies & Legislation
Public consultation for the modification of the biosimilars regulation
Comments (0)
Post your comment